Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Takeda Global Research & Development Center, Inc. |
---|---|
Information provided by: | Takeda Global Research & Development Center, Inc. |
ClinicalTrials.gov Identifier: | NCT00818883 |
The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with TAK-491 in subjects with moderate to severe essential hypertension.
Condition | Intervention | Phase |
---|---|---|
Essential Hypertension |
Drug: TAK-491 and chlorthalidone Drug: TAK-491 and hydrochlorothiazide |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension |
Estimated Enrollment: | 600 |
Study Start Date: | February 2009 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: TAK-491 and chlorthalidone
TAK-491 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching capsules, orally, once daily for up to 10 weeks. For subjects who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment. |
2: Experimental |
Drug: TAK-491 and hydrochlorothiazide
TAK-491 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, capsules, orally, once daily for up to 10 weeks. For subjects who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment. |
According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.
Although most antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of antihypertensive agents. TAK-491 is an angiotensin II receptor blocker being evaluated by Takeda to treat essential hypertension.
Treatments for essential hypertension commonly include use of a thiazide-type diuretic, either alone or as part of combination treatment. Although chlorthalidone was commonly prescribed in the past, its use has widely been replaced with hydrochlorothiazide, presumably due to a lack of available combination products containing chlorthalidone, the assumption that hydrochlorothiazide and chlorthalidone have similar antihypertensive effects and cardiovascular benefits, and the perception that chlorthalidone use is associated with a greater frequency of hypokalemia. However, the frequency of hypokalemia with chlorthalidone use is relatively low in the dose range of 12.5 to 25 mg and these doses have been shown to be associated with potent blood pressure reduction. Several long-term outcomes trials have shown that blood pressure reductions associated with chlorthalidone treatment reduce risk of cardiovascular morbidity and mortality.
Most hypertensive patients require two or more agents to achieve target blood pressure and diuretics are commonly used in combination with other antihypertensive agents. This trial is designed to compare chlorthalidone and hydrochlorothiazide when coadministered with TAK-491.
Subjects in this study will receive either chlorthalidone or hydrochlorothiazide in combination with TAK-491. Total commitment time for this study is about 13 weeks. Subjects will be required to wear a blood pressure monitor for three 24 hours periods during the study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
Other agents that alter blood pressure, including:
Contact: Takeda Study Registration Call Center | 800-778-2860 | medicalinformation@tpna.com |
Study Director: | Executive Medical Director | Takeda Global Research & Development Center, Inc. |
Responsible Party: | Takeda Global Research & Development Center, Inc. ( Sr. VP, Clinical Science ) |
Study ID Numbers: | TAK-491CLD-306 |
Study First Received: | January 7, 2009 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00818883 |
Health Authority: | United States: Food and Drug Administration; Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica; Brazil: Ministry of Health; Chile: Comisión Nacional de Investigación Científica y Tecnológica; Mexico: Federal Commission for Protection Against Health Risks; Peru: Ministry of Health |
Essential Hypertension Hypertensive Blood Pressure, High |
Vascular Disease Cardiovascular Disease Drug Therapy |
Chlorthalidone Vascular Diseases Essential hypertension Hydrochlorothiazide Hypertension |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Natriuretic Agents Therapeutic Uses Physiological Effects of Drugs Diuretics |
Sodium Chloride Symporter Inhibitors Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |